Cramer's Lightning Round- Kicking Myself Over Toll Brothers (4/16/13) + MORE

By SA Editor Miriam Metzinger: Stocks discussed on the Lightning Round segment of Jim Cramer’s Mad Money Program, Tuesday April 16. Bullish Calls:
Toll Brothers (TOL): “We are kicking ourselves. The charitable trust should have been in there buying at $30. That’s okay. It is still a Buy.”
ImmunoGen (IMGN): “It doesn’t have a good royalty arrangement on one of its drugs, but it has other drugs…

Is this meaningful? Or just another movement?    

I was listening to a business talk show in my car the other day. The show's host made an important point.

"Stop talking about the dividend trade," he implored. And he's right.
The "dividend trade" has become shorthand for the mania for dividend-paying stocks. It's been a key theme in the current bull market, though the phrase implies that it's a passing trend…

In any case, I think U.S. Bancorp and Wells Fargo offer more upside from today’s levels than Bank of America.    

Commentary: The real story in the stock market these days is perhaps being told by the Dow Jones Transportation Average. And it’s a potentially worrisome story.

kenyan wrote:So, the Vanguard fund (which I hold via VSIAX) is a bit cheaper and more diversified, with slightly larger companies and a heavier (though still not heavy a la Fama-French purists) value tilt. I don’t like the world "value-y" that some people use, so I’ll say it’s more "valuerific…

April 17 (Bloomberg) — Bob Rice, general managing partner
at Tangent Capital Partners LLC, discusses the strategies in his
book “The Alternative Answer: Non-Traditional Investments That
Drive the World’s Best Performing Portfolios.” Rice talks with
Bloomberg’s Pimm Fox and Carol Massar on Bloomberg Radio’s
“Taking Stock…

Apple (NASDAQ:AAPL) has plummeted precipitously since last fall, off about 45% from its late-2012 peak above $700 a share.
The entire way down, many investors have wondered whether “now” is the time to enter into Apple stock and ride a (theoretical) recovery in shares once the dust settles.
But after Apple plowed through the $400 mark intraday Wednesday, traders better look out…

It’s not just gold bugs getting hit by the yellow metal’s sharp decline.

Filed under: Investing

Syneron Medical has put a familiar person on its CEO throne. The company named Shimon Eckhouse as its new chief executive, effective immediately. He succeeds Louis Scafuri, who will “remain available” to the firm through the current quarter to aid in the transition…